Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Monitoring of timely and delayed vaccinations: a nation-wide registry-based study of Norwegian children aged < 2 years.

Riise ØR, Laake I, Bergsaker MA, Nøkleby H, Haugen IL, Storsæter J.

BMC Pediatr. 2015 Nov 13;15:180. doi: 10.1186/s12887-015-0487-4.

2.

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.

Vaccine. 2013 Dec 16;31(52):6232-8. doi: 10.1016/j.vaccine.2013.10.032. Epub 2013 Oct 29.

PMID:
24176490
3.

Decline in early childhood respiratory tract infections in the Norwegian mother and child cohort study after introduction of pneumococcal conjugate vaccination.

Magnus MC, Vestrheim DF, Nystad W, Håberg SE, Stigum H, London SJ, Bergsaker MA, Caugant DA, Aaberge IS, Nafstad P.

Pediatr Infect Dis J. 2012 Sep;31(9):951-5.

4.

Tracking parental attitudes on vaccination across European countries: The Vaccine Safety, Attitudes, Training and Communication Project (VACSATC).

Stefanoff P, Mamelund SE, Robinson M, Netterlid E, Tuells J, Bergsaker MA, Heijbel H, Yarwood J; VACSATC working group on standardization of attitudinal studies in Europe.

Vaccine. 2010 Aug 9;28(35):5731-7. doi: 10.1016/j.vaccine.2010.06.009. Epub 2010 Jun 15.

PMID:
20558250
5.

[Vaccination--value for money?].

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Kristiansen IS.

Tidsskr Nor Laegeforen. 2006 Oct 19;126(20):2670-3. Norwegian.

6.

[Adverse events after vaccination].

Nøkleby H, Bergsaker MA.

Tidsskr Nor Laegeforen. 2006 Oct 5;126(19):2541-4. Review. Norwegian.

7.

Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine.

Feiring B, Fuglesang J, Oster P, Naess LM, Helland OS, Tilman S, Rosenqvist E, Bergsaker MA, Nøkleby H, Aaberge IS.

Clin Vaccine Immunol. 2006 Jul;13(7):790-6.

8.

Introduction of pneumococcal conjugate vaccine into the Norwegian childhood vaccination programme.

Bergsaker MA, Feiring B.

Euro Surveill. 2006 Feb 2;11(2):E060202.5. No abstract available.

PMID:
16804205
9.

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.

Vaccine. 2006 Jul 17;24(29-30):5690-9. Epub 2006 May 5.

PMID:
16735083

Supplemental Content

Loading ...
Support Center